Cassava Sciences (SAVA) PT Raised to 'Street High' $80 at Maxim Group
Get Alerts SAVA Hot Sheet
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy raised the price target on Cassava Sciences (NASDAQ: SAVA) to $80.00 (from $14.00) while maintaining a Buy rating after the company announced the first set of cognition and behavior data from the P2b extension study of simufilam in mild-moderate Alzheimer's disease (AD).
The analyst commented, "The space is shifting, and SAVA's simufilam is about as advanced as any asset in this new wave of AD therapeutics. The 6-month cog data was the start. The 9-month and 12-month cog data are next, as are two phase 3s (even one with a 6-month end point, unheard of in AD). We break it down below. We have lowered our discount rate to 20%, from 30%, and use a 70% risk adjustment (unchanged), which serves to increase our price target to $80, from $14."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FI) PT Raised to $175 at TD Cowen
- Novartis (NVS) PT Raised to $108 at CFRA
- AGNC Investment Corp (AGNC) PT Lowered to $10.25 at Jones Trading
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot CommentsRelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!